Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases
James S. Wilmott(Melanoma Institute Australia), Michael A. Davies(AstraZeneca (United Kingdom))
Cited by 16
Related Papers
A novel AKT3 mutation in melanoma tumours and cell lines
|British Journal of Cancer|2008|267
Basal and Treatment-Induced Activation of AKT Mediates Resistance to Cell Death by AZD6244 (ARRY-142886) in <i>Braf-</i> Mutant Human Cutaneous Melanoma Cells
|Cancer Research|2010|230
Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results
|Nature Medicine|2023|75
Expression of the class 1 histone deacetylases HDAC8 and 3 are associated with improved survival of patients with metastatic melanoma
|Modern Pathology|2015|44
Validation of an Accurate Automated Multiplex Immunofluorescence Method for Immuno-Profiling Melanoma
|Frontiers in Molecular Biosciences|2022|30